Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

CHRS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Coherus Oncology, Inc.NASDAQ: CHRS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $37.94M (cash outflow) fell 32.9% year over year, behind the +369.3% change in trailing-twelve-month net income.

Context

  • Net income amounted to 398.4% of revenue in FY2025, up 387.7 pp from a year earlier.
  • Net income increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -$101.19M (-160.2%) for the fiscal year ending Dec 2026, a slowdown from the +489.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$37.94M-115.7% QoQ
Last fiscal yearDec 2025
$168.02M+489.4% YoY
LTMMar 2026
$465.5M+369.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.9%-113.0%-80.1 pp
1 year+489.4%-160.2%-649.6 pp
3-year CAGR———
5-year CAGR-32.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
168.02M USD
Year-over-year change
+489.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CHRS compares with its peers on the latest reported figures

  • CHRS's LTM Mar 2026 net income of $465.5M is the largest of the 11 companies compared; the peer median is $58.8M.
  • Its year-over-year change of +369.3% is the 2nd highest of 11, against a peer median of -5.4%.
  • Net income amounts to 992.9% of revenue for CHRS, versus a peer median of 242.8%.
CHRS Competitors Peer median
Net Income for CHRS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CHRSCoherus Oncology, Inc.LTM Mar 2026$465.5M +369.3%—992.9%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$123.33M +55.2%-13.9%356.9%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$103.8M +0.5%-6.4%297.8%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$84.74M -216.1%+23.4%143627.1%
IVVDInvivyd, Inc.LTM Mar 2026$77.6M -45.6%-39.9%138.9%
TARAProtara Therapeutics, Inc.LTM Mar 2026$63.31M +39.4%-4.5%—
OABIOmniAb, Inc.LTM Mar 2026$54.29M -11.4%+42.6%187.8%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$47.84M -17.8%-11.7%2454.6%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$35.76M +37.8%-13.4%—
CDXSCodexis, Inc.LTM Mar 2026$31.99M -57.0%+9.4%41.0%
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$21.94M +461.3%-23.8%28.7%
Peer median (excluding CHRS) $58.8M-5.4%-9.1%242.8%

Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(287.1M)(291.75M)(237.89M)28.51M168.02M
Depreciation & Amortization3.45M3.7M3.79M5.28M3.92M
Deferred Income Tax9.44M0000
Stock-Based Compensation51.36M50.74M43.11M27.8M16.97M
Change in Working Capital42.36M(79.26M)(36.83M)55.89M(5.84M)
Accounts Receivables34.06M13.05M(150.68M)149.35M93.56M
Inventory(6.25M)(47.35M)(46.73M)(31.95M)(17.11M)
Accounts Payables874K(4.55M)23.76M(3.94M)(19.56M)
Other Working Capital13.68M(40.41M)136.83M(57.57M)(62.74M)
Other Non-Cash Items143.05M75.45M52.93M(137.92M)(321.59M)
Operating Cash Flow(37.43M)(241.12M)(174.88M)(20.44M)(138.51M)
Capital Expenditures(1.29M)(2.04M)(286K)00
Acquisitions (Net)1.29M0845K00
Purchases of Investments(182.49M)(127.38M)(19.51M)0(103.84M)
Sales of Investments181.36M0157.64M14.89M21.46M
Other Investing Activities(137.29M)(37.43M)5.95M215.43M457.46M
Investing Cash Flow(138.41M)(166.85M)144.64M230.32M375.09M
Debt Repayment(672K)49.93M0(223.41M)(233.19M)
Common Stock Issued40.9M6.36M74.22M1.46M8.25M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities54.3M(1.96M)(4.62M)34.98M(48.77M)
Financing Cash Flow51.88M54.33M69.6M(186.97M)(273.71M)
Effect of Forex Changes00(12K)00
Net Change in Cash(123.96M)(353.65M)39.34M22.91M(37.13M)
Free Cash Flow(38.72M)(243.16M)(175.17M)(20.44M)(138.51M)

Coherus Oncology, Inc.

NASDAQ:CHRS

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.